Since Polo-like kinase 1(PLK1) and bromodomain 4(BRD4) are both attractive therapeutic targets in acute myeloid leukemia (AML), Lu group developed BRD4 and PLK1 degrader 118 (HBL-4, Fig. 30) based on a dual-target inhibitor BI2536.209 The degrader 118 (HBL-4) induced efficient and fast degradation in human acute leukemia cells tested in vitro and vivo, such as MV4-11, MOLM-13, and KG1. The gene discussed is PLK1; the disease is acute leukemia.